TransMedics Group, Inc. (NASDAQ:TMDX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• TransMedics Group, Inc. has received a consensus recommendation of "Moderate Buy" from ten brokerages, with four analysts rating it as a hold and six as a buy.
• The company's stock has shown strong performance, with a 12-month price objective averaging $125.40, and it opened at $117.43 recently.
• TransMedics reported earnings of $0.92 per share for the last quarter, significantly surpassing estimates and reflecting a 37.7% year-over-year revenue growth.

Shares of TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $125.40.

TMDX has been the subject of several analyst reports. Oppenheimer raised their price target on shares of TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a research note on Tuesday, June 17th. Evercore ISI assumed coverage on shares of TransMedics Group in a research note on Tuesday, September 16th. They set an "outperform" rating and a $155.00 target price for the company. Morgan Stanley lifted their target price on shares of TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a research note on Friday, August 1st. Canaccord Genuity Group lifted their target price on shares of TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a research note on Tuesday, July 15th. Finally, Piper Sandler reissued an "overweight" rating and set a $145.00 target price (up previously from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th.

TransMedics Group Price Performance

TMDX stock opened at $117.43 on Thursday. The company has a fifty day moving average price of $116.15 and a 200-day moving average price of $108.06. The company has a market capitalization of $4.00 billion, a P/E ratio of 60.84 and a beta of 2.18. TransMedics Group has a 52-week low of $55.00 and a 52-week high of $160.80. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.17 and a current ratio of 9.86.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.44. The firm had revenue of $157.37 million during the quarter, compared to the consensus estimate of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The company's revenue for the quarter was up 37.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. As a group, equities analysts expect that TransMedics Group will post 1 EPS for the current year.

Hedge Funds Weigh In On TransMedics Group

A number of hedge funds have recently bought and sold shares of TMDX. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in TransMedics Group by 244.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,113,082 shares of the company's stock worth $209,448,000 after buying an additional 2,209,996 shares during the last quarter. Marshall Wace LLP grew its holdings in TransMedics Group by 258.7% in the second quarter. Marshall Wace LLP now owns 546,787 shares of the company's stock worth $73,275,000 after purchasing an additional 394,340 shares during the period. Capital Fund Management S.A. grew its holdings in TransMedics Group by 100.4% in the first quarter. Capital Fund Management S.A. now owns 252,294 shares of the company's stock worth $16,974,000 after purchasing an additional 126,414 shares during the period. Zevenbergen Capital Investments LLC acquired a new stake in TransMedics Group in the second quarter worth $16,286,000. Finally, Next Century Growth Investors LLC acquired a new stake in TransMedics Group in the second quarter worth $16,049,000. Institutional investors own 99.67% of the company's stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.